ijms-logo

Journal Browser

Journal Browser

Frontiers in Cardiometabolic Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 3264

Special Issue Editor

Special Issue Information

Dear Colleagues,

Cardiometabolic diseases are the result of a combination of unhealthy lifestyle and genetic factors that may lead to obesity, obesity-related euglycaemic insulin resistance, type 2 diabetes mellitus (T2DM), thus contributing to the development of cardiovascular disease (CVD). Together, these metabolic diseases are among the leading causes of death in westernized societies and frequently present themselves as comorbid conditions also for the presence of a prothrombotic tendency. An increased thrombotic tendency in these metabolic disorders stems from platelet hyperactivity, enhanced activity of prothrombotic coagulation factors and impaired fibrinolysis. Furthermore, a low-grade inflammatory response and increased oxidative stress accelerate the atherothrombosis process and result in premature and more severe cardiovascular disease.

This Special Issue is calling both original articles and reviews providing to the readers of IJMS a comprehensive elucidation about dysregulation of the cellular processes involved in the increased thrombotic risk in metabolic diseases characterized by obesity, dyslipidemia, hyperglycemia, and/or insulin resistance.

Dr. Isabella Russo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thrombosis
  • platelets
  • coagulation
  • diabetes
  • obesity
  • insulin resistance
  • metabolic disease
  • cardiovascular diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 1258 KiB  
Review
Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data
by Annunziata Nusca, Francesco Piccirillo, Federico Bernardini, Aurelio De Filippis, Federica Coletti, Fabio Mangiacapra, Elisabetta Ricottini, Rosetta Melfi, Paolo Gallo, Valeria Cammalleri, Nicola Napoli, Gian Paolo Ussia and Francesco Grigioni
Int. J. Mol. Sci. 2022, 23(13), 7261; https://doi.org/10.3390/ijms23137261 - 30 Jun 2022
Cited by 4 | Viewed by 2426
Abstract
Coronary artery disease (CAD) remains one of the most important causes of morbidity and mortality worldwide, and revascularization through percutaneous coronary interventions (PCI) significantly improves survival. In this setting, poor glycaemic control, regardless of diabetes, has been associated with increased incidence of peri-procedural [...] Read more.
Coronary artery disease (CAD) remains one of the most important causes of morbidity and mortality worldwide, and revascularization through percutaneous coronary interventions (PCI) significantly improves survival. In this setting, poor glycaemic control, regardless of diabetes, has been associated with increased incidence of peri-procedural and long-term complications and worse prognosis. Novel antidiabetic agents have represented a paradigm shift in managing patients with diabetes and cardiovascular diseases. However, limited data are reported so far in patients undergoing coronary stenting. This review intends to provide an overview of the biological mechanisms underlying hyperglycaemia-induced vascular damage and the contrasting actions of new antidiabetic drugs. We summarize existing evidence on the effects of these drugs in the setting of PCI, addressing pre-clinical and clinical studies and drug-drug interactions with antiplatelet agents, thus highlighting new opportunities for optimal long-term management of these patients. Full article
(This article belongs to the Special Issue Frontiers in Cardiometabolic Diseases)
Show Figures

Figure 1

Back to TopTop